Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
2 drugs in development
By Therapeutic Area
top 1
R&D Momentum
64/100
Pipeline Velocity
22/100
Trial Completion Rate
94/100
Pipeline Concentration
50/100
Pipeline Freshness
0/100
Strategic Signals
Activity
Last 14 days
Clinical and Genetic Evaluation of Patients With Undiagnosed Disorders Through the Undiagnosed Diseases Network
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
Genomic Sequencing for Evaluation of Uncommon Disease Manifestations Through the Childhood Complex Disease Genomic Section
Deciphering the Genetic Architecture of Autoimmune Diseases
Genome Medical Sequencing for Gene Discovery
Medical Decision-Making in a Virtual Clinical Setting
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases
The International Genetic Basis of Congenital Heart Disease Study
Use of Cysteamine in the Treatment of Cystinosis
Diagnosis and Treatment of Patients With Inborn Errors of Metabolism or Other Genetic Disorders
Maternal Inborn Errors of Metabolism in Pregnancy: A Pregnancy Registry Protocol
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)